Endocyte Stock Price, News & Analysis (NASDAQ:ECYT)

$3.18 +0.03 (+0.95 %)
(As of 02/20/2018 08:18 AM ET)
Previous Close$3.15
Today's Range$3.14 - $3.36
52-Week Range$1.17 - $6.55
Volume632,000 shs
Average Volume393,321 shs
Market Capitalization$152.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.87

About Endocyte (NASDAQ:ECYT)

Endocyte logoEndocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Receive ECYT News and Ratings via Email

Sign-up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ECYT
CUSIP29269A10
Phone765-463-7175

Debt

Debt-to-Equity RatioN/A
Current Ratio24.05%
Quick Ratio24.05%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$70,000.00
Price / Sales2,175.12
Cash FlowN/A
Price / CashN/A
Book Value$3.24 per share
Price / Book0.98

Profitability

Trailing EPS($1.36)
Net Income$-43,880,000.00
Net Margins-82,235.72%
Return on Equity-38.91%
Return on Assets-37.13%

Miscellaneous

Employees76
Outstanding Shares47,880,000

Endocyte (NASDAQ:ECYT) Frequently Asked Questions

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) posted its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.20. The biopharmaceutical company had revenue of $0.03 million for the quarter. Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The company's quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.21) EPS. View Endocyte's Earnings History.

Where is Endocyte's stock going? Where will Endocyte's stock price be in 2018?

2 analysts have issued 12 month target prices for Endocyte's stock. Their predictions range from $7.00 to $7.00. On average, they anticipate Endocyte's share price to reach $7.00 in the next twelve months. View Analyst Ratings for Endocyte.

What are Wall Street analysts saying about Endocyte stock?

Here are some recent quotes from research analysts about Endocyte stock:

  • 1. According to Zacks Investment Research, "Endocyte has very few candidates in its pipeline with all of them in the early or mid-stages of development. With no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth. Endocyte’s products will face intense competition in the market from both large pharma companies and small and mid-sized companies.However, in October 2017, Endocyte accelerated its path to commercialization as it acquired the rights to PSMA-617, being evaluated for the treatment of prostate cancer. The candidate represents a more than $1 billion market opportunity and its development is now the main priority of the company. Currently, the company plans to focus on its most promising programs - lutetium PSMA-617 radioligand therapy and prostate cancer, and CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform. In the last one year, shares of the company have outperformed the industry." (2/15/2018)
  • 2. Cowen Inc analysts commented, "Today a late breaking abstract was presented at the AACR conference with pre-." (4/5/2017)

Who are some of Endocyte's key competitors?

Who are Endocyte's key executives?

Endocyte's management team includes the folowing people:

  • John C. Aplin Ph.D., Independent Chairman of the Board (Age 69)
  • Michael A. Sherman, President, Chief Executive Officer, Director (Age 50)
  • Michael T. Andriole, Chief Financial Officer (Age 44)
  • Philip S. Low Ph.D., Chief Science Officer, Director (Age 67)
  • Michael A. Brinkley, Vice President - Quality (Age 51)
  • Christopher P. Leamon Ph.D., Vice President - Research (Age 49)
  • P. David Mozley M.D., Vice President - Imaging
  • Katherine K. Parker, Vice President of Human Resources (Age 50)
  • Beth A. Taylor, Corporate Controller (Age 49)
  • Cooper Lesley Russell, Director (Age 56)

Who owns Endocyte stock?

Endocyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (3.03%), BlackRock Inc. (2.38%), Millennium Management LLC (0.68%), Renaissance Technologies LLC (0.61%), Geode Capital Management LLC (0.50%) and Goldman Sachs Group Inc. (0.36%). Company insiders that own Endocyte stock include Christopher P Leamon and Philip S Low. View Institutional Ownership Trends for Endocyte.

Who sold Endocyte stock? Who is selling Endocyte stock?

Endocyte's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Spark Investment Management LLC. Company insiders that have sold Endocyte company stock in the last year include Christopher P Leamon and Philip S Low. View Insider Buying and Selling for Endocyte.

Who bought Endocyte stock? Who is buying Endocyte stock?

Endocyte's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., Goldman Sachs Group Inc., EAM Investors LLC, Renaissance Technologies LLC, Geode Capital Management LLC, AXA and Bank of New York Mellon Corp. View Insider Buying and Selling for Endocyte.

How do I buy Endocyte stock?

Shares of Endocyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endocyte's stock price today?

One share of Endocyte stock can currently be purchased for approximately $3.18.

How big of a company is Endocyte?

Endocyte has a market capitalization of $152.26 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-43,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Endocyte employs 76 workers across the globe.

How can I contact Endocyte?

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.


MarketBeat Community Rating for Endocyte (ECYT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  388
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endocyte (NASDAQ:ECYT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.502.502.502.33
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$7.00$4.50
Price Target Upside: 92.84% upside92.84% upside92.84% upside135.60% upside

Endocyte (NASDAQ:ECYT) Consensus Price Target History

Price Target History for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ:ECYT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/2/2017CowenReiterated RatingHoldHighView Rating Details
10/3/2017WedbushUpgradeNeutral -> Outperform$2.00 -> $7.00HighView Rating Details
11/11/2016Credit Suisse GroupReiterated RatingBuy$7.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Endocyte (NASDAQ:ECYT) Earnings History and Estimates Chart

Earnings by Quarter for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ ECYT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.35)($0.55)$0.03 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.25)($0.28)$0.01 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.28)($0.27)$0.01 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.25)($0.26)$0.01 millionViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.21)$0.03 millionViewListenView Earnings Details
8/4/2016Q2($0.26)($0.25)$0.01 millionViewN/AView Earnings Details
5/4/2016Q116($0.25)($0.24)$0.01 millionViewListenView Earnings Details
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details
8/4/2015Q215($0.30)($0.25)$0.01 millionViewN/AView Earnings Details
5/7/2015Q115($0.24)($0.26)$0.01 millionViewN/AView Earnings Details
3/2/2015Q414($0.24)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details
7/29/2014Q214$0.11$0.52$26.62 million$49.17 millionViewN/AView Earnings Details
5/2/2014Q114($0.15)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details
11/5/2013Q3 2013($0.19)($0.08)$15.89 million$16.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.08)($0.10)$15.34 million$16.48 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.02)($0.02)ViewN/AView Earnings Details
11/1/2012Q3 2012$0.01($0.03)ViewN/AView Earnings Details
8/2/2012Q2 2012$0.39($0.12)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.31)($0.27)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.34)($0.30)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.33)($0.36)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.27)($0.35)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.40)($0.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Endocyte (NASDAQ:ECYT) Earnings Estimates

2018 EPS Consensus Estimate: ($0.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.21)($0.21)($0.21)
Q4 20181($0.23)($0.23)($0.23)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Endocyte (NASDAQ:ECYT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Endocyte (NASDAQ ECYT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.86%
Institutional Ownership Percentage: 19.45%
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ ECYT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/28/2017Philip S LowInsiderSell50,511$4.41$222,753.51View SEC Filing  
12/28/2017Philip S LowInsiderSell50,511$4.41$222,753.51354,050View SEC Filing  
12/1/2017Christopher P LeamonVPSell23,231$5.04$117,084.24150,579View SEC Filing  
11/13/2017Philip S LowInsiderBuy5,600$4.84$27,104.00283,005View SEC Filing  
12/30/2016Christopher P. LeamonVPSell23,244$2.55$59,272.20View SEC Filing  
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00206,606View SEC Filing  
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00200,999View SEC Filing  
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00200,999View SEC Filing  
4/9/2014Allen RitterVPSell1,000$21.16$21,160.0034,282View SEC Filing  
3/21/2014Allen RitterVPSell8,000$33.11$264,880.0012,722View SEC Filing  
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00200,819View SEC Filing  
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.0029,154View SEC Filing  
9/16/2013Allen RitterVPSell2,000$17.06$34,120.0015,722View SEC Filing  
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.0029,154View SEC Filing  
8/30/2013Allen RitterVPSell6,000$14.36$86,160.0017,722View SEC Filing  
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.0029,154View SEC Filing  
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endocyte (NASDAQ ECYT) News Headlines

Source:
DateHeadline
Zacks Investment Research Lowers Endocyte (ECYT) to SellZacks Investment Research Lowers Endocyte (ECYT) to Sell
www.americanbankingnews.com - February 15 at 2:48 PM
Endocyte (ECYT) Stock Rating Upgraded by Zacks Investment ResearchEndocyte (ECYT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 9 at 10:12 AM
Endocyte (ECYT) Lowered to Sell at Zacks Investment ResearchEndocyte (ECYT) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 1 at 11:35 AM
Endocyte, Now Included In IBB, Has A Strong Clinical-Stage Asset - Seeking AlphaEndocyte, Now Included In IBB, Has A Strong Clinical-Stage Asset - Seeking Alpha
seekingalpha.com - January 31 at 3:20 PM
Endocyte, Inc. (ECYT) Expected to Post Earnings of -$0.16 Per ShareEndocyte, Inc. (ECYT) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - January 23 at 3:10 PM
Zacks: Brokerages Expect Endocyte, Inc. (ECYT) Will Announce Earnings of -$0.16 Per ShareZacks: Brokerages Expect Endocyte, Inc. (ECYT) Will Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - January 6 at 11:26 AM
Insider Selling: Endocyte, Inc. (ECYT) Insider Sells 50,511 Shares of StockInsider Selling: Endocyte, Inc. (ECYT) Insider Sells 50,511 Shares of Stock
www.americanbankingnews.com - January 2 at 7:04 PM
Endocyte, Inc. (ECYT) Insider Philip S. Low Sells 50,511 SharesEndocyte, Inc. (ECYT) Insider Philip S. Low Sells 50,511 Shares
www.americanbankingnews.com - January 2 at 7:04 PM
Head to Head Contrast: AveXis (AVXS) and Endocyte (ECYT)Head to Head Contrast: AveXis (AVXS) and Endocyte (ECYT)
www.americanbankingnews.com - December 29 at 9:34 PM
Endocyte, Inc. :ECYT-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Endocyte, Inc. :ECYT-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 28 at 1:16 PM
Endocyte (ECYT) Downgraded to "Strong Sell" at ValuEngineEndocyte (ECYT) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - December 21 at 11:26 PM
Zacks: Analysts Anticipate Endocyte, Inc. (ECYT) to Post -$0.16 Earnings Per ShareZacks: Analysts Anticipate Endocyte, Inc. (ECYT) to Post -$0.16 Earnings Per Share
www.americanbankingnews.com - December 21 at 1:14 AM
Endocyte Added to NASDAQ Biotechnology Index  Endocyte Added to NASDAQ Biotechnology Index  
finance.yahoo.com - December 15 at 9:56 AM
Endocyte, Inc. (ECYT) VP Sells $117,084.24 in StockEndocyte, Inc. (ECYT) VP Sells $117,084.24 in Stock
www.americanbankingnews.com - December 4 at 7:00 PM
Why Endocyte, Inc. Stock Briefly Spiked TodayWhy Endocyte, Inc. Stock Briefly Spiked Today
finance.yahoo.com - December 4 at 5:16 PM
Zacks: Brokerages Expect Endocyte, Inc. (ECYT) to Announce -$0.16 EPSZacks: Brokerages Expect Endocyte, Inc. (ECYT) to Announce -$0.16 EPS
www.americanbankingnews.com - December 3 at 5:36 AM
Endocyte, Inc. (ECYT) Lowered to "Sell" at ValuEngineEndocyte, Inc. (ECYT) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - November 26 at 1:38 PM
ETFs with exposure to Endocyte, Inc. : November 21, 2017ETFs with exposure to Endocyte, Inc. : November 21, 2017
finance.yahoo.com - November 21 at 6:22 PM
Endocytes Stunning Strategic Shift - Seeking AlphaEndocyte's Stunning Strategic Shift - Seeking Alpha
seekingalpha.com - November 14 at 11:35 PM
-$0.16 EPS Expected for Endocyte, Inc. (ECYT) This Quarter-$0.16 EPS Expected for Endocyte, Inc. (ECYT) This Quarter
www.americanbankingnews.com - November 14 at 7:08 PM
Philip S. Low Purchases 5,600 Shares of Endocyte, Inc. (ECYT) StockPhilip S. Low Purchases 5,600 Shares of Endocyte, Inc. (ECYT) Stock
www.americanbankingnews.com - November 14 at 5:02 PM
Endocyte to Present at the Jefferies 2017 London Healthcare Conference - GlobeNewswire (press release)Endocyte to Present at the Jefferies 2017 London Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 10 at 7:54 AM
Endocyte to Present at the Jefferies 2017 London Healthcare ConferenceEndocyte to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 10 at 7:54 AM
Wedbush Comments on Endocyte, Inc.s FY2017 Earnings (ECYT)Wedbush Comments on Endocyte, Inc.'s FY2017 Earnings (ECYT)
www.americanbankingnews.com - November 9 at 7:55 AM
Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss - NasdaqEndocyte (ECYT) Posts Narrower-than-Expected Q3 Loss - Nasdaq
www.nasdaq.com - November 8 at 5:22 AM
Edited Transcript of ECYT earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of ECYT earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 5:41 AM
Endocyte Reports Third Quarter Financial Results - GlobeNewswire (press release)Endocyte Reports Third Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - November 7 at 12:39 AM
Endocyte, Inc. (ECYT) Announces Quarterly  Earnings Results, Misses Estimates By $0.20 EPSEndocyte, Inc. (ECYT) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS
www.americanbankingnews.com - November 6 at 11:42 PM
Endocyte, Inc. to Host Earnings CallEndocyte, Inc. to Host Earnings Call
finance.yahoo.com - November 6 at 7:37 PM
Endocyte Reports Third Quarter Financial ResultsEndocyte Reports Third Quarter Financial Results
finance.yahoo.com - November 6 at 7:36 PM
Endocyte reports 3Q lossEndocyte reports 3Q loss
finance.yahoo.com - November 6 at 7:36 PM
Comparing Endocyte (ECYT) & Its RivalsComparing Endocyte (ECYT) & Its Rivals
www.americanbankingnews.com - November 6 at 1:18 AM
Will Endocyte (ECYT) Disappoint This Earnings Season?Will Endocyte (ECYT) Disappoint This Earnings Season?
finance.yahoo.com - November 1 at 12:27 AM
Will Endocyte (ECYT) Disappoint This Earnings Season?Will Endocyte (ECYT) Disappoint This Earnings Season?
finance.yahoo.com - October 31 at 7:24 PM
Endocyte Announces Third Quarter 2017 Earnings Conference Call ... - GlobeNewswire (press release)Endocyte Announces Third Quarter 2017 Earnings Conference Call ... - GlobeNewswire (press release)
globenewswire.com - October 30 at 11:54 PM
Endocyte Announces Third Quarter 2017 Earnings Conference CallEndocyte Announces Third Quarter 2017 Earnings Conference Call
finance.yahoo.com - October 30 at 6:53 PM
Endocyte, Inc. (ECYT) Sees Large Growth in Short InterestEndocyte, Inc. (ECYT) Sees Large Growth in Short Interest
www.americanbankingnews.com - October 26 at 1:20 AM
 Brokerages Anticipate Endocyte, Inc. (ECYT) Will Announce Earnings of -$0.35 Per Share Brokerages Anticipate Endocyte, Inc. (ECYT) Will Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - October 25 at 6:40 AM
Why Endocyte Is Rallying TodayWhy Endocyte Is Rallying Today
www.fool.com - October 18 at 1:02 PM
Critical Analysis: Endocyte (ECYT) and Dipexium Pharmaceuticals (PLXP)Critical Analysis: Endocyte (ECYT) and Dipexium Pharmaceuticals (PLXP)
www.americanbankingnews.com - October 16 at 9:08 AM
Endocyte, Wedbush Analyst Upgrade, and the PSMA-617 Licensing DealEndocyte, Wedbush Analyst Upgrade, and the PSMA-617 Licensing Deal
finance.yahoo.com - October 10 at 3:53 PM
BGNE Hits Record High, SYRS Awaits Catalysts, ALT To Report Data In Q4BGNE Hits Record High, SYRS Awaits Catalysts, ALT To Report Data In Q4
www.nasdaq.com - October 9 at 11:31 PM
Endocyte, Inc. (ECYT) Expected to Post Earnings of -$0.35 Per ShareEndocyte, Inc. (ECYT) Expected to Post Earnings of -$0.35 Per Share
www.americanbankingnews.com - October 6 at 8:32 AM
Q3 2017 EPS Estimates for Endocyte, Inc. Reduced by Analyst (ECYT)Q3 2017 EPS Estimates for Endocyte, Inc. Reduced by Analyst (ECYT)
www.americanbankingnews.com - October 6 at 7:42 AM
ETFs with exposure to Endocyte, Inc. : October 3, 2017ETFs with exposure to Endocyte, Inc. : October 3, 2017
finance.yahoo.com - October 4 at 10:44 AM
Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira LitigationBiotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation
finance.yahoo.com - October 4 at 10:44 AM
Endocytes stock rockets again on heavy volume after license deal for prostate cancer treatment - MarketWatchEndocyte's stock rockets again on heavy volume after license deal for prostate cancer treatment - MarketWatch
www.marketwatch.com - October 3 at 6:04 PM
Why Endocyte, Inc. (ECYT) Stock Is Going Bonkers Today - Investorplace.comWhy Endocyte, Inc. (ECYT) Stock Is Going Bonkers Today - Investorplace.com
investorplace.com - October 3 at 6:04 PM
Endocytes stock rockets again on heavy volume after license deal for prostate cancer treatmentEndocyte's stock rockets again on heavy volume after license deal for prostate cancer treatment
finance.yahoo.com - October 3 at 6:04 PM
Endocyte Inks Deal For Prostate Cancer Candidate, Shares UpEndocyte Inks Deal For Prostate Cancer Candidate, Shares Up
finance.yahoo.com - October 3 at 6:04 PM

SEC Filings

Endocyte (NASDAQ:ECYT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endocyte (NASDAQ:ECYT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endocyte (NASDAQ ECYT) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.